What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Could MS Drug Have a Role in Acute Stroke?Could MS Drug Have a Role in Acute Stroke?
A new study looking at natalizumab to treat stroke showed no effect on the primary endpoint of infarct volume growth, but there was a hint of some clinical benefit. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

No Benefit for Natalizumab Within 9 Hours of Stroke (CME/CE)
(MedPage Today) -- Early data found no benefit on MRI or NIHSS scores for potent monoclonal antibody (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 19, 2016 Category: Cardiology Source Type: news

New EMA Advice for PML Prevention With Tysabri in MSNew EMA Advice for PML Prevention With Tysabri in MS
The European Medicines Agency has released new recommendations on PML prevention with natalizumab in multiple sclerosis. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Natalizumab Ups JCV Seroconversion, Antibody Index in MSNatalizumab Ups JCV Seroconversion, Antibody Index in MS
New data shed some light on the mechanism behind the PML risk with natalizumab and emphasize the need for regular JC virus testing, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 30, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Stratification of Natalizumab-Associated PML RiskStratification of Natalizumab-Associated PML Risk
This consensus paper presents a practical algorithm which can be used to stratify patients with MS according to their risk of developing PML during treatment with natalizumab. Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2016 Category: Pathology Tags: Neurology & Neurosurgery Journal Article Source Type: news

MS Drug Tied to Higher Risk for Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease (Source: WebMD Health)
Source: WebMD Health - January 27, 2016 Category: Consumer Health News Source Type: news

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus
Patients taking Tysabri were more prone to show signs of exposure to JCV, which can cause a brain disease Source: HealthDay Related MedlinePlus Page: Multiple Sclerosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 27, 2016 Category: Consumer Health News Source Type: news

More Tysabri Patients Turn Positive for JC Virus Antibodies (CME/CE)
(MedPage Today) -- Seroconversion rates on treatment much higher than expected (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 27, 2016 Category: Neurology Source Type: news

PML With Natalizumab Despite Recent Negative JCV Test ResultPML With Natalizumab Despite Recent Negative JCV Test Result
Because the first sign of PML was seen in new MRI findings, this case report underlines the value of surveillance imaging in patients receiving natalizumab, researchers say. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Natalizumab in the Pediatric MS PopulationNatalizumab in the Pediatric MS Population
Is natalizumab safe and effective for use in pediatric MS patients who have not responded to other therapies? BMC Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

No Conclusions About MS Drug Superiority (CME/CE)
(MedPage Today) -- Two cohort studies give opposing views of natalizumab versus fingolimod efficacy (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 9, 2015 Category: Neurology Source Type: news

New Data Show Longer Tysabri Dosing Interval in MS Is Feasible (CME/CE)
(MedPage Today) -- But available data remain underpowered to confirm PML risk reduction (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 7, 2015 Category: Neurology Source Type: news

Conversion to JCV Positivity Common With Natalizumab in MS Conversion to JCV Positivity Common With Natalizumab in MS
A study including longitudinal analysis of patients with MS treated with natalizumab shows no link between duration of treatment and conversion to JCV antibody positivity or PML. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news